Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) – Investment analysts at Chardan Capital reduced their FY2022 EPS estimates for shares of Krystal Biotech in a research report issued to clients and investors on Tuesday, November 8th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings per share of ($5.27) for the year, down from their previous estimate of ($4.91). Chardan Capital currently has a “Buy” rating and a $133.00 price target on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is ($5.42) per share. Chardan Capital also issued estimates for Krystal Biotech’s FY2023 earnings at ($4.01) EPS.
Several other analysts also recently weighed in on the company. The Goldman Sachs Group downgraded Krystal Biotech from a “buy” rating to a “neutral” rating and set a $74.00 price objective for the company. in a research report on Wednesday, August 24th. HC Wainwright boosted their price objective on shares of Krystal Biotech from $107.00 to $119.00 and gave the company a “buy” rating in a research report on Monday.
Krystal Biotech Stock Performance
Shares of KRYS stock opened at $77.50 on Friday. The business has a 50-day moving average of $70.66 and a 200 day moving average of $67.69. Krystal Biotech has a 1-year low of $38.86 and a 1-year high of $102.99.
Krystal Biotech (NASDAQ:KRYS – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.02).
Insider Activity at Krystal Biotech
In related news, insider Suma Krishnan sold 823 shares of Krystal Biotech stock in a transaction on Tuesday, November 8th. The shares were sold at an average price of $80.04, for a total value of $65,872.92. Following the sale, the insider now owns 1,726,440 shares in the company, valued at $138,184,257.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Krish S. Krishnan sold 966 shares of Krystal Biotech stock in a transaction that occurred on Tuesday, November 8th. The stock was sold at an average price of $80.05, for a total transaction of $77,328.30. Following the sale, the chief executive officer now directly owns 1,787,722 shares in the company, valued at $143,107,146.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Suma Krishnan sold 823 shares of Krystal Biotech stock in a transaction dated Tuesday, November 8th. The shares were sold at an average price of $80.04, for a total transaction of $65,872.92. Following the transaction, the insider now directly owns 1,726,440 shares of the company’s stock, valued at $138,184,257.60. The disclosure for this sale can be found here. 17.80% of the stock is owned by corporate insiders.
Institutional Trading of Krystal Biotech
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale boosted its holdings in Krystal Biotech by 187.5% in the first quarter. DekaBank Deutsche Girozentrale now owns 25,300 shares of the company’s stock worth $1,693,000 after acquiring an additional 16,500 shares in the last quarter. Merriman Wealth Management LLC purchased a new position in Krystal Biotech in the first quarter worth about $333,000. Arizona State Retirement System lifted its stake in shares of Krystal Biotech by 21.3% in the first quarter. Arizona State Retirement System now owns 4,712 shares of the company’s stock worth $314,000 after buying an additional 827 shares in the last quarter. C WorldWide Group Holding A S grew its holdings in shares of Krystal Biotech by 21.5% during the first quarter. C WorldWide Group Holding A S now owns 225,809 shares of the company’s stock valued at $15,025,000 after buying an additional 40,000 shares during the last quarter. Finally, Commonwealth Equity Services LLC bought a new stake in shares of Krystal Biotech during the first quarter valued at approximately $234,000. Hedge funds and other institutional investors own 81.14% of the company’s stock.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Krystal Biotech, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Krystal Biotech wasn’t on the list.
While Krystal Biotech currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.